On February 9, 2010, the US Food and Drug Administration (FDA) extended its approval of rosuvastatin to include the indication for reducing the risk of stroke, myocardial infarction (MI), and revascularization procedures in individuals who have normal low-density lipoprotein cholesterol (LDL-C) levels and no clinically evident coronary heart disease but have an increased risk based on age, high-sensitivity C-reactive protein (hsCRP) levels, and the presence of at least 1 additional cardiovascular disease risk factor.1 The decision by the FDA was based on results from the Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study, which demonstrated a 44% risk reduction in the primary end point in 17 802 primary prevention patients randomly allocated to treatment with rosuvastatin, 20 mg, compared with placebo.2
Treatment effect by high-sensitivity C-reactive protein (hsCRP) categories. Data are stratified according to 3 different hsCRP cut points: 4.2 mg/L (median), 4.0 mg/L, and 3.0 mg/L (American Heart Association/Centers for Disease Control and Prevention cut point for high risk) (to convert hsCRP to nanomoles per liter, multiply by 9.524). Compared with placebo, treatment with rosuvastatin significantly reduced cardiovascular events in every hsCRP category. Pint indicates interaction P value.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 37
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.